Follow The Filings

Merck & Co., Inc.

Rahway, NJ 4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

  • $526M
  • 13 holdings
  • 2026 Q2
  • +50.7% QoQ
  • Top 5 93.3%

Portfolio

2026 Q2, filed 8/7/2026, top 12 of 13 holdings

Top 5 93.3%, top 10 99.8%

  1. PSNL, Personalis 35.8%
  2. MRNA, Moderna 30.7%
  3. KYMR, Kymera Therapeutics 16.8%
  4. AKTS, Aktis Oncology 5.9%
  5. EIKN, Eikon Therapeutics 4.1%
  6. TRDA, Entrada Therapeutics 2.4%
  7. STRO, Sutro Biopharma 1.7%
  8. ALEC, Alector 1.4%
  9. Evaxion Biotech A/s 0.7%
  10. Viridian Therapeutics 0.3%
  11. Xilio Therapeutics 0.2%
  12. Tuhura Biosciences 0.0%
  13. Other 0.0%

AUM over time

2026 Q2 $526M +50.7% QoQ
2025 Q3: $228M 2025 Q3: $228M
Q3 2025
2025 Q4: $276M, +21.1% QoQ 2025 Q4: $276M, +21.1% QoQ
Q4
2026 Q1: $349M, +26.4% QoQ 2026 Q1: $349M, +26.4% QoQ
Q1 2026
2026 Q2: $526M, +50.7% QoQ 2026 Q2: $526M, +50.7% QoQ
Q2

Book

2025 Q4 2025 Q3, filed 17 Feb, long equity only

Download CSV Download Excel All activity
PSNL, Personalis 40.47% Hold 14,044,943 $7.96 $112M — —
MRNA, Moderna 24.64% Hold 2,308,190 $29.49 $68M — —
KYMR, Kymera Therapeutics 21.75% Hold 772,165 $77.81 $60M — —
TRDA, Entrada Therapeutics 6.47% Hold 1,739,768 $10.28 $18M — —
Evaxion Biotech A/s 2.10% Hold 1,214,126 $4.77 $5.8M — —
ALEC, Alector 2.00% Hold 3,545,719 $1.56 $5.5M — —
Sutro Biopharma 1.14% Reduce −90.0% 272,351 $11.57 $3.2M −2,451,158 +$786K
Viridian Therapeutics 1.05% Hold 93,414 $31.12 $2.9M — —
Xilio Therapeutics 0.34% Hold 1,483,758 $0.6402 $950K — —
Carisma Therapeutics 0.02% Hold 1,473,240 $0.0430 $63K — —
Neuphoria Therapeutics 0.01% Hold 10,027 $3.88 $39K — —
Tuhura Biosciences 0.00% Hold 13,950 $0.7567 $11K — —

Exits / last held

Gone since 2025 Q3, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
Lava Therapeutics 0.79% Exit 0 $1.56 $1.8M −1,149,345 −$1.8M

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2025 Q3. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

4 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 13 $526M +50.7% 13F-HR 8/7/2026 000031015826000210
2026 Q1 14 $349M +26.4% 13F-HR 5/13/2026 000031015826000141
2025 Q4 12 $276M +21.1% 13F-HR 2/17/2026 000031015826000055
2025 Q3 13 $228M — 13F-HR 11/12/2025 000031015825000063

About

Merck & Co., Inc.

4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

SEC filing name
Merck & Co., Inc.
Location
Rahway, NJ
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf